Bevacizumab for retinopathy of prematurity and neurodevelopment

J AAPOS. 2024 Feb;28(1):103786. doi: 10.1016/j.jaapos.2023.08.018. Epub 2023 Nov 4.

Authors

David K Wallace¹; Writing Committee for PEDIG¹

Affiliation

¹ Vanderbilt Eye Institute, Nashville, Tennessee.

PMID: 37926389
DOI: 10.1016/j.jaapos.2023.08.018

No abstract available

Publication types

Letter
Comment

MeSH terms

Angiogenesis Inhibitors / therapeutic use
Bevacizumab / therapeutic use
Gestational Age
Humans
Infant, Newborn
Infant, Premature
Intravitreal Injections
Retinopathy of Prematurity* / drug therapy

Substances

Bevacizumab
Angiogenesis Inhibitors